Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | PRCP | P42785 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392579 | 1.00 | S1PR3 (0.59) | S1PR3ALDH1A1PRCPKDM4EMAPT | |
| SCHEMBL29776727 | 1.00 | S1PR3 (0.59) | S1PR3ALDH1A1PRCPKDM4EMAPT | |
| SCHEMBL4573899 | 1.00 | S1PR3 (0.59) | S1PR3ALDH1A1PRCPKDM4EMAPT | |
| SCHEMBL3557711 | 1.00 | S1PR3 (0.59) | S1PR3ALDH1A1PRCPKDM4EMAPT | |
| SCHEMBL4573866 | 1.00 | S1PR3 (0.59) | S1PR3ALDH1A1PRCPKDM4EMAPT | |
| SCHEMBL4751119 | 1.00 | S1PR3 (0.59) | S1PR3ALDH1A1PRCPKDM4EMAPT | |
| SCHEMBL3553011 | 1.00 | S1PR3 (0.59) | S1PR3ALDH1A1PRCPKDM4EMAPT | |
| SCHEMBL3553095 | 1.00 | S1PR3 (0.59) | S1PR3ALDH1A1PRCPKDM4EMAPT | |
| SCHEMBL3555702 | 1.00 | S1PR3 (0.59) | S1PR3ALDH1A1PRCPKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL4574538 | 0.99 | S1PR3 (0.58) | S1PR3ALDH1A1PRCPKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029408-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8592465-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2008128179-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255213-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | S1PR3 1038/4885ALDH1A1 606/4885PRCP 2694/4885 |
| US-20080255213-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | SRM, SAT1, SMS | S1PR3 679/4885ALDH1A1 185/4885PRCP 1865/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | S1PR3 3237/4885ALDH1A1 619/4885PRCP 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.